Catalyst Pharmaceuticals ... (CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Dal...

CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.

The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat...

Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.38 per share a year ago.

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst tradin...

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

This IBD 50 holding holds top notch ratings amid a market downturn. The post Catalyst Pharma Battles To All-Time High After Huge Patent Lawsuit Win appeared first on Investor's Business Daily.

Big Money continues buying Catalyst Pharmaceuticals, Inc. (CPRX).

Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in t...